CD274 and non-small cell lung carcinoma: The IMpower010 trial showed a DFS benefit with atezolizumab, a PD-L1 inhibitor, versus best supportive care after adjuvant chemotherapy in patients with resected early stage NSCLC, with a pronounced benefit in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells, and no new safety signals.